---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-037446"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T13:22:42.468656+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cumberland Q3 2023: net loss $1.0M, revenue $10.1M, YTD adj. EPS $0.29

## Summary
- Net loss of $1.0M; adjusted earnings $260K ($0.02/share); YTD net income $15K, adj. EPS $0.29.
- Product revenue $10.1M (Kristalose $3.9M, Vibativ $2.8M, Sancuso $1.9M, Caldolor $1.2M).
- New $25M revolving credit facility with Pinnacle Bank; $12.9M drawn at quarter-end.
- Sancuso acquisition transition completed; FDA approved new mfg plant; supplies underway Q4 2023.
- NOPAIN Act may provide separate Medicare reimbursement for Caldolor from 2025; ifetroban Phase II trials ongoing.

## SEC filing metadata
- accession: 0001628280-23-037446
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828023037446/0001628280-23-037446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828023037446/cpix-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-037446
- JSON: https://secwatch.observer/filing/0001628280-23-037446.json
- Plain text: https://secwatch.observer/filing/0001628280-23-037446.txt

## Key facts
- Earnings Releases
  CUMBERLAND PHARMACEUTICALS INC reported financial results for the three and nine months ended September 30, 2023.
  - Period: the three and nine months ended September 30, 2023
  - Result: reported results
  source text: On November 7, 2023, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three and nine months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1087294/000162828023037446/0001628280-23-037446-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.